Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Crypto News Today: $431M Shaken Out as ETH and XRP Reset, While Cofounder Builds Pepeto
-
Crypto Update: Ethereum’s Four-Minute Settlement Proposal Meets Remittix Earn’s 18-22% APY Test Offer
-
Chainlink Price Prediction: LINK Near $11.30 After LG CNS Deal as Remittix Earn Readies Aave, Morpho and Fluid Pools
-
Litecoin Price Prediction: Can LTC Reclaim $63 as Remittix Plans a 64.3% Presale Price Increase?
-
SOL, ETH and Remittix: Best Crypto Presale to Buy as Earn Prepares Aave, Morpho and Fluid Pools?
-
Crypto News: Bitcoin and XRP Face Oil’s $117 Close as Remittix Invites Earn Testers With Weekly Payouts
-
Bitcoin News: Tesla-SpaceX Merger Talks Put Their BTC Holdings in Focus as Remittix Plans a 300M RTX Burn
-
Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform
-
Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform
-
Nekteck Makes Everyday Relaxation and Recovery More Accessible With Practical Wellness Products
-
Crypto News: Remittix Announces 300 Million RTX Burn at Launch as JPMorgan Brings Two Tokenized Funds to Solana, Building the Case for a $300 SOL Price Prediction
-
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
-
LexisNexis Coplogic Solutions Introduces Field Clarity for LexisNexis® Desk Officer Reporting System (DORS) at IACP 2026
-
Ethereum Price Prediction: ETH Near $2,324 as Four-Minute Proposal Meets Remittix’s 100-Tester Earn Offer
-
Crypto News Today: Swiss Retail Bitcoin ETF Approval Meets Remittix’s $0.28 Entry and November Launch Countdown
-
Dr. Anna Nolin Highlights Human-Centered Leadership as Schools Navigate the Next Phase of Artificial Intelligence
-
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
-
Monster Energy and Call of Duty® Take Over Cosm Los Angeles for Immersive Modern Warfare® 4 Launch Celebration
-
Bitcoin Price News: ETFs Added $1B Earlier This Week as Remittix Recruits 100 Earn Testers
-
XRP Price Today: XRP Near $1.29 as Wallets Hit 8.24M and Remittix Prepares a 20% Supply Cut
-
New Crypto Watch: Monero Gains Around 2% as Remittix’s $33M Raise Meets a Planned 300M RTX Burn
-
Binance New Listing Watch: Alpha Removes Seven Tokens as Remittix Prepares Its November 24 Debut
-
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Pati
-
Come Back to Firefox: Mozilla launches its most ambitious campaign yet to bring people back to the independent alternative to big tech browsers
-
TRON Price Prediction: $23M Revenue Report Beats ETH and SOL Combined as Remittix Plans 41 More Fiat Currencies
-
AirTripMaker Launches Comprehensive Flight Tickets to India Routes Guide from the USA and Canada to Major Indian Destinations
-
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
-
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
-
Beyond GRC: DigitalXForce Pioneers AI-Powered Risk Operations with Global X-ROC™ Rollout
-
NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
-
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
-
Binance Acquires BTEXCHAIN, Accelerating the Integration of AI and Global Digital Asset Trading Technology
-
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
-
Best AI Tools for Small Business Marketing (2026): CapCut Featured for Creating Professional Video and Visual Content by Expert Consumers
-
Beyond Live Streaming: Tango Gives Back by Supporting Cancer Detection in Ukraine
-
Borr Drilling Limited - Prospector 5 Rig Incident
-
SI vs. AI: Super Intelligence Anomaly Outbreaks Trump’d by Clinton Legacy Tech (Veterans First for America)
-
Best Broadband Provider for Small Businesses UK (2026): Love Business Group Recognised for Helping SMEs Compare Business Broadband Options by Expert Consumers
-
Best Protective iPhone Cases for 2026: Top Slim and Drop-Protection Options for iPhone 18 Pro & iPhone 18 Pro Max Recommended by Consumer365
-
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
-
KFSH Expands Virtual Care Pathways to Bring Specialized Follow-Up Closer to Patients
-
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and
-
Cryptocurrency News: Solana Goes 85x Faster as Pepeto Early Buyers Line Up for a Run
-
Bitcoin Price News Today: BTC Holds $81K After a $406M Wipeout While Pepeto Buyers Line Up
-
Frontier Medicines Presents Promising Anti-Tumor Activity from Phase 1/2 PROSPER Trial of FMC-376 in a Highly Resistant Patient Population of KRAS G12C-Mutant NSCLC at ESMO 2026
-
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
-
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
-
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
-
Binance Coin Price Holds $730 After 1.6M Burn as Buyers Bet Pepeto Can Be the Next BNB
-
Next Crypto to Make You Rich: Pepeto’s Call Pulls Buyers Away From XRP and Cardano
